Clinuvel Pharmaceuticals Ltd
ASX:CUV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
AU |
|
Entrada Therapeutics Inc
NASDAQ:TRDA
|
US |
|
Sociedad Quimica y Minera de Chile SA
NYSE:SQM
|
CL |
|
S
|
Sun Vending Technology PCL
SET:SVT
|
TH |
|
K
|
Knowles Corp
SWB:1K3
|
US |
|
Atea ASA
F:MKL
|
NO |
|
OMV AG
VSE:OMV
|
AT |
|
Arteris Inc
NASDAQ:AIP
|
US |
Wall St Price Targets
CUV Price Targets Summary
Clinuvel Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for CUV is 21.04 AUD with a low forecast of 9.62 AUD and a high forecast of 42.84 AUD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is CUV's stock price target?
Price Target
21.04
AUD
According to Wall Street analysts, the average 1-year price target for CUV is 21.04 AUD with a low forecast of 9.62 AUD and a high forecast of 42.84 AUD.
What is the Revenue forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 39%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
8%
The compound annual growth rate for Gross Profit over the next 8 years is 8%.
What is the Operating Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
9%
The compound annual growth rate for Operating Income over the next 8 years is 9%.
What is the Pre-Tax Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
20%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 20%.
What is the Net Income forecast for Clinuvel Pharmaceuticals Ltd?
Projected CAGR
11%
The compound annual growth rate for Net Income over the next 8 years is 11%.
